Riskified Joins Forces with HUMAN to Help Merchants Embrace Trusted AI Shopping Agent Commerce
13.8.2025 15:00:00 CEST | Business Wire | Press Release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud prevention and risk intelligence, announced a new partnership with HUMAN Security, a leading cybersecurity company, with a shared vision to advance a unified security framework that helps merchants win and grow safely via emerging agentic channels. The partnership underscores their joint commitment to leverage their respective industry-leading AI platforms and expansive network insights to secure the next era of digital commerce.
While fully autonomous shopping agents have yet to reach mainstream adoption, consumers are increasingly using large language models (LLMs) like ChatGPT, Claude, Gemini, Grok, Llama, and Perplexity to research products, compare prices, and discover deals. This behavior, combined with the rapid technology advancement including announcements of LLM browser experiences from LLM leaders, creates both new opportunities and risks. For merchants, early adopters of AI-driven shopping stand to win new customers and increase conversion rates. Still, rules-based fraud management can fail when an AI agent transacts, removing key behavioral signals and leading to more false declines or undetected fraud.
Without a trust framework, merchants risk revenue loss, inventory manipulation, and reputational damage. Early data from Riskified’s merchant network shows LLM-referred traffic to be more risky in certain industries. For example LLM-referred traffic from a large ticketing merchant was 2.3x more risky compared to Google search traffic. In another example, an electronics merchant showed 1.8x riskier traffic. Riskified has also identified early signs of automated reseller arbitrage, where AI agents are deployed to rapidly strip inventory and then resell at marked-up prices via fraudulent storefronts, which other agents would then recommend. Left unchecked, these tactics can disrupt pricing strategies, erode customer trust, and cause significant revenue loss for merchants.
Riskified and HUMAN are among the first to address these challenges directly. Alongside the partnership with HUMAN, Riskified is introducing multiple solutions and tools designed to advance fraud and abuse prevention in the world of agentic ecommerce. These include:
- AI Agent Approve: MCP Server Package on AWS Marketplace for supply-side (merchants) and demand-side (LLMs) to communicate with the Riskified platform APIs and accelerate the safe adoption of AI shopping agents.
- AI Agent Intelligence: Dashboard views in the Riskified Control Center for monitoring ecommerce orders originating from AI shopping agents.
- AI Agent Policy Builder: Configuration and enforcement of agentic policy abuse, including the detection of programmatic returns abuse, reseller arbitrage, and promo abuse.
By aligning HUMAN’s recently launched HUMAN Sightline featuring AgenticTrust with Riskified’s ecommerce risk management expertise in fraud prevention, chargeback protection, and policy abuse prevention, merchants can apply consistent trust policies and transaction decisions across both human and AI-driven interactions. This collaborative approach is designed to help merchants confidently accept more legitimate AI-driven purchases, block sophisticated fraud, and protect customer relationships.
"In a world where AI agents transact on behalf of individuals, resolving identity and trust becomes more complex. By working with HUMAN and developing new agentic tools and capabilities, we give merchants a way to safely embrace this shift, turning what could be a threat into a new, profitable digital channel," said Assaf Feldman, CTO and Co-Founder of Riskified.
"We are incredibly excited to be working with Riskified as a launch partner, bringing together HUMAN Sightline featuring AgenticTrust with their ecommerce risk management expertise to help establish a trusted ecosystem for agentic commerce," said John Searby, Chief Strategy Officer, HUMAN Security. "HUMAN provides the trust layer and visibility to identify and govern AI shopping agent interactions, empowering merchants to set and enforce ‘trust or not’ policies. Riskified brings deep expertise in ecommerce transaction fraud prevention, chargeback protection, and policy abuse prevention. Together, we enable merchants to approve more legitimate AI-driven orders, reduce false declines, and protect margins, setting the standard for how agentic commerce can grow safely and profitably."
For more information on Riskified’s perspectives, tools, and capabilities for agentic commerce, visit Riskified’s blog.
About Riskified
Riskified (NYSE: RSKD) empowers businesses to unleash ecommerce growth by outsmarting risk. Many of the world’s biggest brands and publicly traded companies selling online rely on Riskified for guaranteed protection against chargebacks, to fight fraud and policy abuse at scale, and to improve customer retention. Developed and managed by the largest team of ecommerce risk analysts, data scientists, and researchers, the Riskified ecommerce risk management platform analyzes the individual behind each interaction to provide real-time decisions and robust identity-based insights. Learn more at www.riskified.com.
About HUMAN
HUMAN is a leading cybersecurity company committed to protecting the integrity of the digital world. We enable trusted interactions and transactions across the full spectrum of online actors: humans, bots and AI agents. The Human Defense Platform safeguards the entire customer journey with high-fidelity decision-making that defends against bots, fraud, and digital threats. Each week, HUMAN verifies 20 trillion digital interactions, providing unparalleled telemetry data to enable rapid, effective responses to even the most sophisticated threats. Recognized by our customers as a G2 Leader, HUMAN continues to set the standard in cybersecurity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813021841/en/
Contacts
Investor Relations:
Chett Mandel
Head of Investor Relations
ir@riskified.com
Corporate Communications:
Cristina Dinozo
Senior Director of Communications
press@riskified.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom